Research program on Hypertrophic cardiomyopathy inSphynx breed We greatly thank the numerous breeders and owners whoalready sent to us Sphynx samples, with complete documentation. The hypertrophic cardiomyopathy (or HCM) is a cardiacdisease whose genetic causes remain unknown in the Sphynx breed. This cardiac disease has a possible fatal issue for thecat; no treatment is available yet. A program research has been settled by Antagene toidentify the genetic cause of the Sphynx HCM. To get more information, click here 56.09 KB
In order to help the researches, we needimperatively : - a sample toextract DNA (2-3 mLof blood in an EDTA tube; if not possible, buccal swab) of each Sphynx, even if the cat isunaffected. - the copy ofthe clinical results (echocardiogram, electrocardiogram) performed by the vet.Any clinical evolution is interesting for us. - the copy ofthe pedigree of each Sphynx - thesampling certificate downloadable on the website Sampling certificate.pdf 138.30 KB 30.03.2011 10:03
. We guarantee the confidentiality about the transmittedinformation. The participation to the research program is free. A geneticcertificate can not be delivered with the results obtained through the researchprogram. Research advancing (31st of May 2011) To date, 220 Sphynx samples have been collected. 49Sphynx have been diagnosed affected of HCM and 13 of heart trouble. 158 havebeen diagnosed HCM free. Thanks to the owners involvement, 2 hearts have beenentrusted to us for anatomical pathological analysis. Thanks to provided pedigree and to information dataconcerning other elder affected cats, a wide pedigree is on process to confirmthe mode of inheritance of the disease and to find the existing relationshipsbetween the different cats affected by the disease. The Antagene research program on Sphynx HCM is establishedin collaboration with the ENVA (Pr Chetboul, Dr Abitbol) and the ENVT (DrDiquelou, Dr Raymond-Letron). We need Sphynx samples, affected and unaffected. Contact: mageane@antagene.com Project manager : Aurélie Fangain Head of R&D : Anne Thomas
| 
